FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Markets

Pricing
Access
Commercial
Launch Tracking

M&A Watch

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Company

Epic Pharma LLC

Pharmaceutical intelligence for Epic Pharma LLC with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

RegulatoryAugust 14, 2026

FDA Submission Update for Furosemide by Epic Pharma

Epic Pharma LLC has submitted a supplemental application (NDA018569) for Furosemide, which is currently under standard review by the FDA. This application may lead to new indications or enhanced formulations for Furosemide, a widely used cardiovascular diuretic.